-
摘要:
目的 探讨前列腺癌患者近距离治疗疗效及并发症。 方法 前列腺癌患者27例, 年龄63~81岁, 平均75岁。临床分期:T1cN0M016例, T2aN0M011例; Gleason评分:5分14例, 6分13例; 血清前列腺特异性抗原(prostate specific antigen, PSA)2.8~14.6 μg/L, 平均8.5 μg/L。采用125I粒子近距离治疗, 治疗剂量D90为140~155 Gy, 观察治疗疗效及并发症。27例患者治疗前后均未使用内分泌治疗。 结果 27例患者随访12~74个月, 平均44个月。近距离治疗后27例前列腺癌患者最低血清PSA中位数为0.18 μg/L, 2例患者最低血清PSA在1.0 μg/L以上; 治疗后1年患者血清PSA中位数为0.71 μg/L, 平均为0.92 μg/L, 17例患者血清PSA在1.0 μg/L以下; 2例患者分别于治疗后30及48个月出现生化复发, 复发率7%(2/27)。治疗后2例患者出现急性尿潴留, 予保留导尿1周后好转; 24例治疗后出现不同程度的尿路刺激症, 均在治疗后6~12个月内好转; 无1例出现前列腺直肠瘘。治疗前17例有勃起功能; 治疗后10例仍保留不同程度的勃起功能, 7例出现勃起功能障碍(占41%)。 结论 前列腺癌近距离治疗对于中低危前列腺癌疗效肯定, 并发症少, 多数患者可以保留性功能。 Abstract:Objective To evaluate the effectiveness and complications of prostate brachytherapy. Methods We enrolled 27 prostate cancer patients aged 63 to 81 years(mean:75 years)in our study, with 16 at the clinical stage of T1cN0M0, 11 at T2aN0M0, and 14 with Gleason score of 5, 13 with Gleason score of 6. Their serum prostate specific antigen(PSA)levels ranged 2.8-18.6 μg/L(mean:8.5 μg/L). All of them underwent 125I seed implantation with the D90 of 140-155 Gy and had the serum PSA levels routinely determined after the procedure.Effectiveness and complications were also observed. None of the 27 patients were treated with hormone therapy. Results Follow-up ranged from 12 to 74 months(mean:44 months). The median nadir PSA was 0.18 μg/L, with only 2 above 1.0 μg/L. One year after brachytherapy, the median level of serum PSA was 0.71 μg/L(mean:0.92 μg/L), and 17 with the level under 1.0 μg/L. Two patients(7%)experienced biochemical failure at the 30 month and 48 month after the procedure. Two patients(7%)developed acute urinary retention, which was released after catheterization for 1 week. Low urinary tract symptoms were observed in 24 patients, which were improved 6-12 months later. No prostate-rectal fistula was observed. Seventeen patients erected efficiently before brachytherapy, while 10 preserved erection in different levels after brachytherapy. The incidence of erectile dysfunction was 41%(7/17). Conclusion Prostate brachytherapy is an effective treatment for low- and intermediate-risk patients with acceptable complications. Most patients can preserve sexual function after this procedure. -
Key words:
- prostate carcinoma /
- brachytherapy /
- prostate specific antigen
-
[1] Nag S.Brachytherapy for prostate cancer:summary of American Brachytherapy Society recommendations[J].Semin Urol Oncol, 2000, 18:133-136. http://cn.bing.com/academic/profile?id=22e1518b4f4cb88da1d92804498877bf&encoded=0&v=paper_preview&mkt=zh-cn [2] Roach Ⅲ, Hanks G, Thames H, et al.Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO phoenix consensus conference[J].IntJ RadiatOncol Biol Phys, 2006, 65:965-974. doi: 10.1016/j.ijrobp.2006.04.029 [3] Taira AV, Merrick GS, Butler WM, et al.Long-term out-come forclinically localized prostate cancertreated with permanent interstitial brachytherapy[J/OL].Int J Radiat Oncol Biol Phys (2010-06-02).http://www.sciencedirect.com/science/journal/03603016. [4] Mayadev J, Merrick GS, Reed JR, et al.Permanent prostate brachytherapy in prostate glands < 20 cm[J].Int J Radiat Oncol Biol Phys, 2010, 76:1450-1455. doi: 10.1016/j.ijrobp.2009.04.014 [5] Mitchell DM, Swindell R, Elliott T, et al.Analysis of prostate-specitic antigen bounce after I125 permanent seed implant for localised prostate cancer[J].Radiother Oncol, 2008, 88:102-107. doi: 10.1016/j.radonc.2008.04.004 [6] Ellis WJ.Prostate brachytherapy[J].Cancer Met Rev, 2002, 21:125-129. doi: 10.1023/A:1020871707029 [7] South Cape Urology.Why Brachytherapy[R/OL].http://www.southcapeurology.co.za/brachytherapy/why.html. [8] Stamey TA, Caldwell M, McNeal JE, et al.The prostatespecific antigen era in the United States is over for prostate cancer:What happened in the last 20 years[J].J Urol, 2004, 172:1297-1301. doi: 10.1097/01.ju.0000139993.51181.5d [9] Zeitman AL, Coen JJ, Shipley WU, et al.Radical radiation therapy in the management of prostatic adenocarcinoma:the initial prostate specific antigen value as a predictor of treatment outcome[J].J Urol, 1994, 151:640-645. doi: 10.1016/S0022-5347(17)35036-X [10] Merrick GS, Bulter WM, Lief JH, et al.Five-year biochemical outcome after prostate brachytherapy for hormonena ve men < or=62 years of age[J].Int J Radiat Oncol Biol Phys, 2001, 50:1253-1257. doi: 10.1016/S0360-3016(01)01539-5 [11] Pinkawa M, Piroth MD, Holy R, etal.Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer[J].Radiother Oncol, 2010, 96:25-29. doi: 10.1016/j.radonc.2010.02.010 [12] Iannuzzi CM, Stock RG, Stone NN.PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer[J].Radiat Oncol Investig, 1999, 7:30-35. doi: 10.1002/(SICI)1520-6823(1999)7:1<30::AID-ROI4>3.0.CO;2-8 [13] Ray ME, Thanes HD, Levy LB, etal.PSAnadir predicts biochemical and distatantfailures afterexternal beamradiotherapy for prostate cancer:a mult-institutional analysis[J].Int J Radiat Oncol Biol Phys, 2006, 64:1140-1150. doi: 10.1016/j.ijrobp.2005.07.006 [14] Stone NN, Stock RG.Complications following permanent prostate brachytherapy[J].Euro Urol, 2002, 41:427-433. doi: 10.1016/S0302-2838(02)00019-2
点击查看大图
计量
- 文章访问数: 149
- HTML全文浏览量: 47
- PDF下载量: 7
- 被引次数: 0